BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38099401)

  • 1. Update on the current and future use of CAR-T to treat multiple myeloma.
    Gahvari Z; Brunner M; Schmidt T; Callander NS
    Eur J Haematol; 2024 Apr; 112(4):493-503. PubMed ID: 38099401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma.
    Miller K; Hashmi H; Rajeeve S
    Front Oncol; 2024; 14():1398902. PubMed ID: 38800372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CAR-T therapy for multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2023; 64(11):1456-1464. PubMed ID: 38072434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
    Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
    Front Immunol; 2022; 13():991092. PubMed ID: 36119032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood.
    Lee WH; Graham CE; Wiggin HR; Nolan HK; Graham KJ; Korell F; Leick MB; Barselau AL; Emmanuel-Alejandro E; Trailor MA; Gildea JM; Preffer F; Frigault MJ; Maus MV; Gallagher KME
    Cytometry B Clin Cytom; 2024 May; 106(3):162-170. PubMed ID: 38418432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
    Ghanem B; Shi L
    BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
    Fang J; Zhou F
    Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
    Anderson LD
    Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence not salvage.
    Sborov DW; Fortuna GG; Hayden PJ
    Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
    Parikh RH; Lonial S
    CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact.
    Hosoya H; Rodriguez-Otero P; Sidana S; Borrello IM
    Am Soc Clin Oncol Educ Book; 2023 Jun; 43():e389860. PubMed ID: 37290016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent updates on CAR T clinical trials for multiple myeloma.
    Lin Q; Zhao J; Song Y; Liu D
    Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
    Fischer L; Grieb N; Platzbecker U; Vucinic V; Merz M
    Eur J Haematol; 2024 Jan; 112(1):19-27. PubMed ID: 37547971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.